Who is sponsoring NCT05520684?

NCT05520684 is sponsored by Trabzon Arakli Bayram Halil Public Hospital.

What drugs are being tested in NCT05520684?

Interventions in NCT05520684: urine culture and urinalysis.

What condition does NCT05520684 study?

NCT05520684 studies Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection.

Is NCT05520684 still recruiting?

NCT05520684 is currently status unknown. Last updated 1 September 2022.

Last reviewed 2022-09-01 · How we verify

NCT05520684

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Asymptomatic Bacteriuria, Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk

Status unknown Last updated 1 September 2022

What this trial tests

trial testing urine culture and urinalysis in Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection in 120 participants. Status unknown.

Timeline

15 February 2022

Primary endpoint
1 November 2022

1 January 2023

Quick facts

Lead sponsor	Trabzon Arakli Bayram Halil Public Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	15 February 2022
Primary completion	1 November 2022
Estimated completion	1 January 2023
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

urine culture and urinalysis

Conditions studied

Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection — all drugs for Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection →

Sponsor

Trabzon Arakli Bayram Halil Public Hospital

Who can join

18 and older, female only, with Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The SGLT2 inhibitors have changed the treatment of type 2 diabetes mellitus in recent years, especially in patients with cardiovascular or renal disease. However, the association between SGLT2 inhibitors and urinary tract infection (UTI) risk is controversial. Moreover, it is not known whether asymptomatic bacteriuria or urinalysis abnormality at the initiation of SGLT2 inhibitors are risk factors for UTI in women. There is not enough data to recommend or not to recommend for performing urinalysis or urine culture test before initiation of SGLT2 inhibitors. The aim of the study is to investigate the effect of asymptomatic bacteriuria or urinalysis abnormality at the initiation of SGLT2 inhibitors on UTI risk in a prospective cohort of women with type 2 diabetes mellitus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05520684 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Trabzon Arakli Bayram Halil Public Hospital
Last refreshed: 1 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05520684.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing